Credit: Photo by Getty.
In a recent trial, led by Cedars-Sinai Cancer investigators, nine patients whose tumors were resistant to androgen-blocking therapy continued that therapy but were also given a CD105 inhibitor called carotuximab. Forty percent of those patients experienced progression-free survival, based on radiographic imaging.